{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:03:38Z","timestamp":1780448618248,"version":"3.54.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:00:00Z","timestamp":1688342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:00:00Z","timestamp":1688342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Childhood-onset ANCA-associated vasculitides (AAV) are characterized by necrotizing inflammation and include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Pediatric data is scare and there have been no prior studies examining the characteristics of pediatric AAV in Central California.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study comprised AAV patients \u226418 years of age, diagnosed between 2010 and 2021, in Central California. We analyzed initial presentation including demographics, clinical, laboratory characteristics, treatment, and initial outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 21 patients with AAV, 12 were categorized as MPA and 9 with GPA. Median age at diagnosis was 13.7 years in MPA cohort and 14 years in GPA. MPA cohort were majority females (92% versus 44%). 57% of the cohort were racial\/ethnic minority including Hispanics (n\u2009=\u20099), Asians (n\u2009=\u20092), multiracial (n\u2009=\u20091) and 43% were white (n\u2009=\u20099). MPA patients were more frequently Hispanic (67%), meanwhile GPA patients were frequently white (78%). Median duration of symptoms prior to diagnosis was 14 days in MPA cohort and 21 days in GPA cohort. Renal involvement was frequent (100% in MPA and 78% in GPA). GPA cohort had frequent ear, nose and throat (ENT) involvement (89%). All patients were ANCA positive. All Hispanic patients were MPO positive, meanwhile 89% of white patients were PR3 positive. MPA cohort tended towards more severe disease with 67% requiring ICU admission and 50% requiring dialysis. Two deaths were reported in MPA cohort, related to Aspergillus pneumonia and pulmonary hemorrhage. In MPA cohort, 42% received cyclophosphamide in combination with steroids and 42% received rituximab in combination with steroids. GPA patients received cyclophosphamide, either with steroids alone (78%) or in combination with steroids and rituximab (22%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Microscopic polyangiitis was the most frequent AAV subtype with female preponderance, shorter duration of symptoms at onset and higher proportion of racial\/ ethnic minority patients. Hispanic children demonstrated frequent MPO positivity. Trends towards higher rates of ICU requirement and need for dialysis upon initial presentation was noted in MPA. Patients with MPA received rituximab more frequently. Future prospective studies are needed to understand differences in presentation and outcomes in childhood onset AAV between diverse racial-ethnic groups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12969-023-00853-4","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T04:01:38Z","timestamp":1688356898000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Childhood-Onset ANCA- Associated Vasculitis: single center experience from Central California"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1102-0678","authenticated-orcid":false,"given":"Deepika","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukesh","family":"Sukumaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,3]]},"reference":[{"issue":"1","key":"853_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.berh.2018.10.003","volume":"32","author":"RA Watts","year":"2018","unstructured":"Watts RA, Robson J. Introduction, epidemiology and classification of vasculitis. Best Pract Res Clin Rheumatol. 2018;32(1):3\u201320.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"853_CR2","doi-asserted-by":"crossref","unstructured":"Jariwala MP, Laxer RM. Primary Vasculitis in Childhood: GPA and MPA in Childhood. Front Pead. 2018;6.","DOI":"10.3389\/fped.2018.00226"},{"issue":"1","key":"853_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13052-017-0364-x","volume":"43","author":"M Calatroni","year":"2017","unstructured":"Calatroni M, Oliva E, Gianfreda D, Gregorini G, Allinovi M, Ramirez GA, et al. ANCA-associated vasculitis in childhood: recent advances. Ital J Pediatr. 2017;43(1):46.","journal-title":"Ital J Pediatr"},{"issue":"1","key":"853_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1546-0096-9-12","volume":"9","author":"N Arulkumaran","year":"2011","unstructured":"Arulkumaran N, Jawad S, Smith SW, Harper L, Brogan P, Pusey CD, et al. Long- term outcome of paediatric patients with ANCA vasculitis. Pediatr Rheumatol. 2011;9(1):12.","journal-title":"Pediatr Rheumatol"},{"issue":"suppl1","key":"853_CR5","first-page":"i104","volume":"30","author":"A-S Sacri","year":"2015","unstructured":"Sacri A-S, Chambaraud T, Ranchin B, Florkin B, S\u00e9e H, Decramer S, et al. Clinical characteristics and outcomes of childhood-onset ANCA-associated vasculitis: a french nationwide study. Nephrol Dialysis Transplantation. 2015;30(suppl1):i104\u2013i12.","journal-title":"Nephrol Dialysis Transplantation"},{"issue":"2","key":"853_CR6","doi-asserted-by":"publisher","first-page":"440","DOI":"10.3899\/jrheum.090688","volume":"37","author":"S GRISARU","year":"2010","unstructured":"GRISARU S, YUEN GWH, MIETTUNEN PM. Incidence of Wegener\u2019s granulomatosis in children. J Rhuematol. 2010;37(2):440\u20132.","journal-title":"J Rhuematol"},{"key":"853_CR7","doi-asserted-by":"crossref","unstructured":"Berti A, Cornec D, Crowson CS, Specks U, Matteson EL. The epidemiology of Antineutrophil cytoplasmic Autoantibody-Associated Vasculitis in Olmsted County, Minnesota: a twenty-year US Population-Based study. Arthritis & rheumatology (Hoboken, NJ). 2017;69(12):2338\u201350.","DOI":"10.1002\/art.40313"},{"issue":"9","key":"853_CR8","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1093\/rheumatology\/kez597","volume":"59","author":"AT Nilsen","year":"2020","unstructured":"Nilsen AT, Karlsen C, Bakland G, Watts R, Luqmani R, Koldingsnes W. Increasing incidence and prevalence of ANCA-associated vasculitis in Northern Norway. Rheumatology (Oxford). 2020;59(9):2316\u201324.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"853_CR9","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1002\/art.39729","volume":"68","author":"DA Cabral","year":"2016","unstructured":"Cabral DA, Canter DL, Muscal E, Nanda K, Wahezi DM, Spalding SJ, et al. Comparing presenting clinical features in 48 children with microscopic polyangiitis to 183 children who have granulomatosis with polyangiitis (Wegener\u2019s): an ARChiVe Cohort Study. Arthritis & Rheumatology. 2016;68(10):2514\u201326.","journal-title":"Arthritis & Rheumatology"},{"key":"853_CR10","doi-asserted-by":"crossref","unstructured":"Mahi SL, Bahram S, Harambat J, Allard L, Merlin E, Belot A et al. Pediatric ANCA vasculitis: clinical presentation, treatment, and outcomes in a french retrospective study. Pediatric nephrology (Berlin, Germany). 2023.","DOI":"10.1007\/s00467-022-05855-0"},{"issue":"11","key":"853_CR11","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1093\/rheumatology\/kex293","volume":"56","author":"FA Pearce","year":"2017","unstructured":"Pearce FA, Craven A, Merkel PA, Luqmani RA, Watts RA. Global ethnic and geographic differences in the clinical presentations of anti-neutrophil cytoplasm antibody\u2013associated vasculitis. Rheumatology. 2017;56(11):1962\u20139.","journal-title":"Rheumatology"},{"issue":"1","key":"853_CR12","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s13075-018-1708-7","volume":"20","author":"J Li","year":"2018","unstructured":"Li J, Cui Z, Long JY, Huang W, Wang JW, Wang H, et al. The frequency of ANCA-associated vasculitis in a national database of hospitalized patients in China. Arthritis Res therapy. 2018;20(1):226.","journal-title":"Arthritis Res therapy"},{"issue":"1","key":"853_CR13","first-page":"44","volume":"28","author":"VR Pimentel-Quiroz","year":"2022","unstructured":"Pimentel-Quiroz VR, Sattui SE, Ugarte-Gil MF, Alarc\u00f3n GS. ANCA-Associated Vasculitis in Latin America: a systematic literature review: about their epidemiology and their clinical features. JCR: J Clin Rheumatol. 2022;28(1):44\u201351.","journal-title":"JCR: J Clin Rheumatol"},{"issue":"6S","key":"853_CR14","first-page":"S246","volume":"27","author":"VR Pimentel-Quiroz","year":"2021","unstructured":"Pimentel-Quiroz VR, S\u00e1nchez-Torres A, Acevedo-V\u00e1squez E, Gamboa-C\u00e1rdenas RV, Re\u00e1tegui-Sokolova C, Medina-Chinch\u00f3n M, et al. Demographic and clinical features of ANCA-Associated Vasculitides in a peruvian Tertiary Center. JCR: J Clin Rheumatol. 2021;27(6S):S246\u2013S51.","journal-title":"JCR: J Clin Rheumatol"},{"issue":"10","key":"853_CR15","first-page":"1916","volume":"50","author":"S Fujimoto","year":"2011","unstructured":"Fujimoto S, Watts RA, Kobayashi S, Suzuki K, Jayne DR, Scott DG, et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. Rheumatology (Oxford. England). 2011;50(10):1916\u201320.","journal-title":"England)"},{"issue":"5","key":"853_CR16","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s10067-014-2617-z","volume":"34","author":"AG Sreih","year":"2015","unstructured":"Sreih AG, Mandhadi R, Aldaghlawi F, Khan A, Irshad V, Finn K, et al. ANCA-associated vasculitis in hispanic Americans: an unrecognized severity. Clin Rheumatol. 2015;34(5):943\u20138.","journal-title":"Clin Rheumatol"},{"issue":"2","key":"853_CR17","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10067-021-05916-z","volume":"41","author":"S Lee","year":"2022","unstructured":"Lee S, Injean P, Tran P, Panikkath L, Salto L, Downey C. ANCA-associated vasculitis in caucasian and Hispanics of the Inland Empire of Southern California. Clin Rheumatol. 2022;41(2):549\u201356.","journal-title":"Clin Rheumatol"},{"issue":"8","key":"853_CR18","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrrheum.2014.103","volume":"10","author":"JC Jennette","year":"2014","unstructured":"Jennette JC, Falk RJ. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat Rev Rheumatol. 2014;10(8):463\u201373.","journal-title":"Nat Rev Rheumatol"},{"key":"853_CR19","unstructured":"U.S. Census bureau quickfacts: Fresno county, California (n.d.). Retrieved April 3., 2023, [Available from: https:\/\/www.census.gov\/quickfacts\/fact\/table\/fresnocountycalifornia\/PST045222."},{"key":"853_CR20","unstructured":"U. S. Census bureau quickfacts: Kern county, california. (n.d.). Retrieved April 3, 2023 [Available from: https:\/\/www.census.gov\/quickfacts\/fact\/table\/kerncountycalifornia\/PST045222."},{"key":"853_CR21","unstructured":"U. S. Census bureau quickfacts: Tulare county, california. (n.d.). Retrieved April 3, 2023, [Available from: https:\/\/www.census.gov\/quickfacts\/fact\/table\/tularecountycalifornia\/PST045222."},{"key":"853_CR22","unstructured":"U. S. Census bureau quickfacts: California. Retrieved June 9, from https:\/\/www.census.gov\/quickfacts\/CA."},{"issue":"7","key":"853_CR23","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1136\/ard.2005.046300","volume":"65","author":"S Ozen","year":"2006","unstructured":"Ozen S, Ruperto N, Dillon MJ, Bagga A, Barron K, Davin JC, et al. EULAR\/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis. 2006;65(7):936\u201341.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"853_CR24","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1136\/ard.2006.054593","volume":"66","author":"R Watts","year":"2007","unstructured":"Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66(2):222\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"853_CR25","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1681\/ASN.2010050477","volume":"21","author":"AE Berden","year":"2010","unstructured":"Berden AE, Ferrario F, Hagen EC, Jayne DR, Jennette JC, Joh K, et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrology: JASN. 2010;21(10):1628\u201336.","journal-title":"J Am Soc Nephrology: JASN"},{"key":"853_CR26","unstructured":"USDA Rural-Urban Commuting Area Codes, Retrieved April 19., 2023 [Available from: https:\/\/www.ers.usda.gov\/data-products\/rural-urban-commuting-area-codes\/."},{"key":"853_CR27","doi-asserted-by":"publisher","first-page":"857813","DOI":"10.3389\/fimmu.2022.857813","volume":"13","author":"J Yang","year":"2022","unstructured":"Yang J, Yang Y, Xu Y, Zhou L, Zhou L, Yin X, et al. Clinical and renal histology findings and different responses to induction treatment affecting the Long-Term Renal Outcomes of Children with ANCA-Associated Vasculitis: a single-center cohort analysis. Front Immunol. 2022;13:857813.","journal-title":"Front Immunol"},{"issue":"961","key":"853_CR28","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1136\/pgmj.2005.034215","volume":"81","author":"M Chen","year":"2005","unstructured":"Chen M, Yu F, Zhang Y, Zhao MH. Clinical [corrected] and pathological characteristics of chinese patients with antineutrophil cytoplasmic autoantibody associated systemic vasculitides: a study of 426 patients from a single centre. Postgrad Med J. 2005;81(961):723\u20137.","journal-title":"Postgrad Med J"},{"issue":"2","key":"853_CR29","doi-asserted-by":"publisher","first-page":"e491","DOI":"10.1097\/RHU.0000000000001775","volume":"28","author":"E Santacruz-Sandoval","year":"2022","unstructured":"Santacruz-Sandoval E, L\u00f3pez-Bonilla J, Guevara-Calder\u00f3n LA, Nieto-Aristiz\u00e1bal I, Ruiz-Ordo\u00f1ez I, Ca\u00f1as CA, et al. Clinical characteristics and outcomes of patients with ANCA-Associated Vasculitides in a colombian hospital. J Clin rheumatology: practical Rep rheumatic Musculoskelet Dis. 2022;28(2):e491\u2013e7.","journal-title":"J Clin rheumatology: practical Rep rheumatic Musculoskelet Dis"},{"issue":"2","key":"853_CR30","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1136\/ard.60.2.170","volume":"60","author":"RA Watts","year":"2001","unstructured":"Watts RA, Gonzalez-Gay MA, Lane SE, Garcia-Porrua C, Bentham G, Scott DG. Geoepidemiology of systemic vasculitis: comparison of the incidence in two regions of Europe. Ann Rheum Dis. 2001;60(2):170\u20132.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"853_CR31","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.autrev.2013.06.016","volume":"12","author":"JA G\u00f3mez-Puerta","year":"2013","unstructured":"G\u00f3mez-Puerta JA, Gedmintas L, Costenbader KH. The association between silica exposure and development of ANCA-associated vasculitis: systematic review and meta-analysis. Autoimmun rev. 2013;12(12):1129\u201335.","journal-title":"Autoimmun rev"},{"issue":"9","key":"853_CR32","doi-asserted-by":"publisher","first-page":"e0137196","DOI":"10.1371\/journal.pone.0137196","volume":"10","author":"P Willeke","year":"2015","unstructured":"Willeke P, Schl\u00fcter B, Sauerland C, Becker H, Reuter S, Jacobi A, et al. Farm exposure as a Differential risk factor in ANCA-Associated Vasculitis. PLoS ONE. 2015;10(9):e0137196.","journal-title":"PLoS ONE"},{"key":"853_CR33","unstructured":"Valley Fever. (Coccidioidomycosis) Statistics, Centers for Disease Control and Prevention, Retreived May 31,2023."},{"key":"853_CR34","unstructured":"California\u2019s Central Valley. : Regional Characteristics, US Geological Survey Retrieved June 20,2023."},{"issue":"3","key":"853_CR35","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3899\/jrheum.160866","volume":"44","author":"YX Chen","year":"2017","unstructured":"Chen YX, Xu J, Pan XX, Shen PY, Li X, Ren H, et al. Histopathological classification and renal outcome in patients with Antineutrophil cytoplasmic antibodies-associated renal vasculitis: a study of 186 patients and Metaanalysis. J Rheumatol. 2017;44(3):304\u201313.","journal-title":"J Rheumatol"},{"issue":"8","key":"853_CR36","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1681\/ASN.2005080870","volume":"17","author":"RA de Lind","year":"2006","unstructured":"de Lind RA, Hauer HA, Wolterbeek R, Jayne DR, Gaskin G, Rasmussen N, et al. Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: a prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrology: JASN. 2006;17(8):2264\u201374.","journal-title":"J Am Soc Nephrology: JASN"},{"key":"853_CR37","doi-asserted-by":"crossref","unstructured":"Morishita KA, Moorthy LN, Lubieniecka JM, Twilt M, Yeung RSM, Toth MB et al. Early Outcomes in Children with Antineutrophil cytoplasmic Antibody-Associated Vasculitis. Arthritis & rheumatology (Hoboken, NJ). 2017;69(7):1470\u20139.","DOI":"10.1002\/art.40112"},{"key":"853_CR38","doi-asserted-by":"crossref","unstructured":"Rhee RL, Hogan SL, Poulton CJ, McGregor JA, Landis JR, Falk RJ et al. Trends in Long-Term Outcomes among patients with Antineutrophil cytoplasmic Antibody-Associated Vasculitis with Renal Disease. Arthritis & rheumatology (Hoboken, NJ). 2016;68(7):1711\u201320.","DOI":"10.1002\/art.39614"},{"key":"853_CR39","unstructured":"S\u00e1nchez \u00c1lamo B, Moi L, Bajema I, Faurschou M, Flossmann O, Hauser T et al. Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis. Nephrol Dialysis Transplantation. 2023."},{"issue":"6","key":"853_CR40","doi-asserted-by":"publisher","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","volume":"116","author":"GS Hoffman","year":"1992","unstructured":"Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116(6):488\u201398.","journal-title":"Ann Intern Med"},{"issue":"1","key":"853_CR41","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/art.20928","volume":"53","author":"E Reinhold-Keller","year":"2005","unstructured":"Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, Gross WL. Stable incidence of primary systemic vasculitides over five years: results from the german vasculitis register. Arthritis Care Res. 2005;53(1):93\u20139.","journal-title":"Arthritis Care Res"},{"key":"853_CR42","doi-asserted-by":"crossref","unstructured":"Mahi S-l, Bahram S, Harambat J, Allard L, Merlin E, Belot A et al. Pediatric ANCA vasculitis: clinical presentation, treatment, and outcomes in a french retrospective study. Pediatr Nephrol. 2023.","DOI":"10.1007\/s00467-022-05855-0"},{"key":"853_CR43","unstructured":"U. S. Census bureau quickfacts: United States (n.d.). Retrieved June 7, from https:\/\/www.census.gov\/quickfacts\/fact\/table\/US\/RHI725221."},{"issue":"1","key":"853_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.md.0000104742.42401.e2","volume":"83","author":"BA Pons-Estel","year":"2004","unstructured":"Pons-Estel BA, Catoggio LJ, Cardiel MH, Soriano ER, Gentiletti S, Villa AR, et al. The GLADEL multinational latin american prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among \u201cHispanics. Medicine. 2004;83(1):1\u201317.","journal-title":"Medicine"},{"issue":"2","key":"853_CR45","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1136\/ard.2010.131482","volume":"70","author":"PI Burgos","year":"2011","unstructured":"Burgos PI, McGwin G, Pons-Estel GJ, Reveille JD, Alarc\u00f3n GS, Vil\u00e1 LM. US patients of hispanic and african ancestry develop lupus nephritis early in the disease course: data from LUMINA, a multiethnic US cohort (LUMINA LXXIV). Ann Rheum Dis. 2011;70(2):393\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"853_CR46","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1002\/acr.24590","volume":"74","author":"KA Morishita","year":"2022","unstructured":"Morishita KA, Wagner-Weiner L, Yen EY, Sivaraman V, James KE, Gerstbacher D, et al. Consensus Treatment plans for severe Pediatric Antineutrophil cytoplasmic Antibody\u2013Associated Vasculitis. Arthritis Care Res. 2022;74(9):1550\u20138.","journal-title":"Arthritis Care Res"},{"issue":"3","key":"853_CR47","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones RB, Cohen Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis. N Engl J Med. 2010;363(3):211\u201320.","journal-title":"N Engl J Med"},{"issue":"3","key":"853_CR48","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. N Engl J Med. 2010;363(3):221\u201332.","journal-title":"N Engl J Med"},{"key":"853_CR49","doi-asserted-by":"crossref","unstructured":"Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G et al. 2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the management of Antineutrophil cytoplasmic Antibody-Associated Vasculitis. Arthritis & rheumatology (Hoboken, NJ). 2021;73(8):1366\u201383.","DOI":"10.1002\/art.41773"},{"issue":"4s","key":"853_CR50","first-page":"1","volume":"100","author":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases","year":"2021","unstructured":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4s):1\u2013s276.","journal-title":"Kidney Int"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-023-00853-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-023-00853-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-023-00853-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T04:05:11Z","timestamp":1688357111000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-023-00853-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,3]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["853"],"URL":"https:\/\/doi.org\/10.1186\/s12969-023-00853-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2813965\/v1","asserted-by":"object"}]},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,3]]},"assertion":[{"value":"19 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board at Valley Children\u2019s Healthcare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"66"}}